OPTI.GB OptiBiotix Health plc

TIDMOPTI

RNS Number : 1774Z

OptiBiotix Health PLC

19 May 2021

Opti B i otix Health plc

( "Opti Bi o t ix" or the "Company")

SkinBioTherapeutics plc shareholding

OptiBi otix Health p lc (AI M : OPTI), a life sciences busi ness d e vel o ping co m p o u n ds to tack le o besit y, high choleste r ol, diabetes and skincare, announces that its entire shareholding in SkinBioTherapeutics plc (AIM: SBTX) consisting of 36,138,569 ordinary shares representing 23.1% of SkinBioTherapeutics plc's total issued share capital, has been dematerialised and transferred to a nominee CREST account (Dowgate Wealth). OptiBiotix plc remains the beneficial owner of the transferred 36,138,569 ordinary shares.

There has been no change in the Company's overall beneficial holding of its SkinBioTherapeutics plc shareholding which in total consists of 36,138,569 representing 23.1% of SkinBioTherapeutics plc's total issued share capital.

This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

For further information, please contact:

 
 OptiBiotix Health plc                                   www.optibiotix.com 
 Neil Davidson, Chairman                         Contact via Walbrook below 
 Stephen O'Hara, Chief Executive 
 
 Cairn Financial Advisers LLP (NOMAD)                    Tel: 020 7213 0880 
 Liam Murray / Jo Turner / Ludovico Lazzaretti 
 
 Cenkos Securities plc (Broker)                          Tel: 020 7397 8900 
 Callum Davidson / Neil McDonald 
 Michael Johnson / Russell Kerr (Sales) 
 
 Walbrook PR Ltd                                         Mob: 07876 741 001 
 Anna Dunphy 
 
 

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

HOLSFSFEUEFSEEI

(END) Dow Jones Newswires

May 19, 2021 09:00 ET (13:00 GMT)

OptiBiotix Health (AQSE:OPTI.GB)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024

OptiBiotix Health (AQSE:OPTI.GB)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024